Key result
Pre-operative VA-ECMO bridging linked to ~3-fold higher 30-day mortality in ADHF-CS vs. medical therapy.
Why the study?
Outcomes associated with different bridging strategies in patients with acute decompensated heart failure-related cardiogenic shock bridged to durable LVAD or heart transplantation were not well described.
Cohort (n=8,777)
Yes
Answers are grounded in this paper and cite their sources.
Supports individualized bridging decisions in ADHF-CS; hypothesis-generating and should not yet change practice.
AIMS: To describe outcomes associated with bridging strategies in patients with acute decompensated heart failure-related cardiogenic shock (ADHF-CS) bridged to durable left ventricular assist device (LVAD) or heart transplantation (HTx). METHODS AND RESULTS: Durable LVAD or HTx recipients from 2014 to 2019 with pre-operative ADHF-CS were identified in the Society of Thoracic Surgeons Adult Cardiac Surgery Database and stratified by bridging strategy. The primary outcome was operative or 30-day post-operative mortality. Secondary outcomes included post-operative major bleeding. Exploratory comparisons between bridging strategies and outcomes were performed using overlap weighting with and without covariate adjustment. Among 9783 patients with pre-operative CS, 8777 (89.7%) had ADHF-CS. Medical therapy (n = 5013) was the most common bridging strategy, followed by intra-aortic balloon pump (IABP; n = 2816), catheter-based temporary mechanical circulatory support (TMCS; n = 417), and veno-arterial extracorporeal membrane oxygenation (VA-ECMO; n = 465). Mortality was highest in patients bridged with VA-ECMO (22%), followed by catheter-based TMCS (10%), IABP (9%), and medical therapy (7%). Adverse post-operative outcomes were more frequent in LVAD recipients compared with HTx recipients. CONCLUSION: Among patients with ADHF-CS bridged to HTx or durable LVAD, the highest rates of death and adverse events during index hospitalization were observed in those bridged with VA-ECMO, followed by catheter-based TMCS, IABP, and medical therapy. Patients who received durable LVAD had higher rates of post-operative complications compared with HTx recipients. Prospective trials are needed to define optimal bridging strategies in patients with ADHF-CS.
No takes yet. Share an insight, caveat, or question.
Varshney et al. (2023) conducted a cohort in Acute decompensated heart failure-related cardiogenic shock (ADHF-CS) (n=8,777). Pre-operative bridging strategies (VA-ECMO, catheter-based TMCS, IABP) vs. Medical therapy alone was evaluated on Composite of death at 30-days after surgery or operative death during index hospitalization (p=<0.01). Among patients with ADHF-CS bridged to cardiac replacement, pre-operative bridging with VA-ECMO was associated with the highest operative or 30-day mortality compared to medical therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: